Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

October 28, 2021

New York Stock Exchange US Health Care Pharmaceuticals earnings 67 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Grace, and hello everyone. It's great to have you join us for Merck's third quarter 2021 conference call. On the line today, we'll hear from Rob Davis, who serves as our Chief Executive Officer; Frank Clyburn, President of Human Health; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs. Prior to beginning, let me highlight a couple of points. In our GAAP results, you'll notice certain items like acquisition-related charges, restructuring costs, and some other things. Please be aware that these have been left out of our non-GAAP results, and a reconciliation is available in our press release. I want to remind everyone that certain remarks we're making today might qualify as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These remarks reflect Merck Management's present beliefs and carry substantial risks and uncertainties. Should our underlying assumptions turn out to be wrong or uncertainties come to pass, actual outcomes could vary materially from what's described in those forward-looking statements. Our SEC filings, including Item 1A in the 2020 10-K, spell out specific risk factors and cautionary statements that might lead the company's actual results to differ materially from any projections in the forward-looking statements we're making this morning. Merck has no obligation to publicly update any forward-looking statements. A slide presentation will go along with our speakers' prepared remarks during today's call. That presentation, along with today's earnings release and our SEC filings, can all be found in the Investor Relations section of Merck's website. So with that, let me hand things over to Rob.

Rob Davis

executive
#2

Thanks, Peter. Good morning to all of you, and I appreciate you being on the call today. It's a real pleasure to share that we've made substantial headway on the growth and strategic priorities that matter most to us during Merck's first complete quarter operating as a leaner, more focused, science-driven organization. Momentum in our business is strong. We've hit important clinical milestones, seized a major business development chance that aligns with our strategy, and delivered commercially to produce a robust quarter; beyond that, we're moving with care and speed, which shows in how quickly we advanced our investigational COVID-19 antiviral, molnupiravir, and filed for Emergency Use Authorization with the FDA without delay. This is an exciting moment for Merck, and we're committed to capitalizing on our recent wins as we carry out our mission of delivering innovations that save and improve lives, while also striving to generate long-term value for patients and shareholders alike. Dean will walk through the substantial pipeline advances we're achieving shortly. Before that, though, I want to congratulate him, our research colleagues, and our partners at Ridgeback Biotherapeutics for the meaningful clinical data we recently announced concerning molnupiravir's development. Since the pandemic began, Merck has looked for ways to bring its scientific know-how into the global battle against COVID-19, and we're delighted to now be able to make a real difference. As you know, in a planned interim analysis of our Phase III trial involving at-risk, nonhospitalized adult patients with mild-to-moderate COVID-19, molnupiravir cut the risk of hospitalization or death by roughly 50% versus placebo. Given those findings and after consulting with the FDA, we halted our trial ahead of schedule; we're currently collaborating with the FDA while the agency reviews our EUA application, and we anticipate next month's advisory committee discussion. I'm happy with how we're progressing toward securing supply and purchase commitments with many governments and health care systems globally, and with how well our push to build supply quickly has gone. I'm also proud that we'll be able to reach patients worldwide via voluntary license agreements, tiered pricing tied to what countries can afford, and our arrangement with the Medicines Patent Pool. We've also made a significant move to strengthen our pipeline through business development, which is a core strategic priority. The announced purchase of Acceleron is a prime illustration of our drive to find and incorporate the best external science to complement what we do ourselves. Acceleron's lead product candidate, sotatercept, could become foundational as an add-on therapy for treating pulmonary arterial hypertension, a condition where there's a serious need for a new agent capable of potentially targeting the underlying illness rather than merely its symptoms. We are eager for our tender offer to wrap up soon and for the regulatory clearances we need so the deal can be finalized. With the possibility of multibillion-dollar peak sales and commercial exclusivity stretching well into the next decade, sotatercept is able to drive meaningful revenue growth during the KEYTRUDA LOE period — a key quality of this target and of possible future ones. Dean and I will keep collaborating with our team to find further scientifically compelling business development opportunities, while we also keep advancing a strong and expanding internal pipeline. This quarter our business did extremely well, and the team keeps showing outstanding, focused execution; we posted very strong commercial and financial results, with meaningful growth throughout our Oncology, Vaccines and Animal Health businesses and even larger growth in earnings. As anticipated, GARDASIL sales were especially strong, since we gained from a sharp rise in manufacturing output and from having more doses available to help meet ongoing robust underlying demand. We believe the momentum we're witnessing will carry on through the end of the year, positioning us for continued growth over the next several years. We stay committed to our work of transforming how we operate by evolving our operating model so it is leaner, nimbler and more digitally enabled. My leadership team is completely united behind the need for Merck to operate with more speed, urgency and agility in every part of our business. We have to stay ahead of the changing external environment so we can make the significant investments needed to deliver future innovations that will address unmet medical needs around the globe. By doing so, we intend to deliver important medicines and vaccines to patients, while we keep driving long-term sustainable growth and value creation for all of our stakeholders. Last, I want to call attention to the recent publication of Merck's Environmental, Social and Governance Progress Report. This year's report calls out important updates on metrics and goals concerning our 4 ESG priority areas, which cover access to health; our employees, including their health and safety as well as engagement and diversity; environmental sustainability; and ethics and values. These ESG efforts rest on the core values that have always steered our mission and underpin our business strategy. We look forward to giving ongoing updates on these important efforts. With that, I'll hand it over to Frank to go through the details behind our Human Health performance.

Frank Clyburn

executive
#3

Appreciate that, Rob. Morning, everyone. Like Rob pointed out, the forward thrust in our Human Health segment carried over into Q3, and we posted 17% expansion once you strip out currency movements; we've kept putting money to work urgently behind patient activation efforts, which sharpen patient understanding and help bring physician office visits, oncology screenings, and vaccination rates back toward more typical volumes. Those steps, while ultimately a win for patient health, also delivered a substantial lift to our portfolio that is mostly administered by physicians during the quarter. Within the United States, we take encouragement from wellness visits and surgical procedures holding at largely standard volumes. On the oncology side, though screening rates and diagnoses keep getting better, they regrettably remain under where they sat before COVID, and that weighs on new patient starts. Beyond the United States, our performance stays robust, even with pandemic-related drag persisting in some markets; shifting now to how our major brands performed in Q3. Everything I say will be on an ex exchange basis. For oncology, KEYTRUDA revenue climbed 21%, reaching $4.5 billion, which speaks to sustained powerful worldwide demand. Across the United States, KEYTRUDA keeps showing lasting traction in every major tumor type, helped by growth from newer launches like KEYNOTE-522 in neoadjuvant adjuvant triple-negative breast cancer. KEYTRUDA keeps widening its already formidable lead across the IO class overall, lifting both new and total patient market share. KEYTRUDA holds onto its number one spot in lung cancer, winning over 8 of every 10 eligible new patients even as competition persists. Beyond lung, the key tumors fueling growth take in renal cell carcinoma, triple-negative breast, MSI high, esophageal, plus head and neck. We're also energized by the fresh approval and imminent launch of KEYNOTE-826, the first anti-PD-1 combination cleared as a first-line therapy for cervical cancer. Beyond the United States, KEYTRUDA's expansion keeps being powered by lung cancer indications along with the continuing launches in head and neck and renal cell carcinoma. We continue to see the opportunity to extend our reach into earlier treatment lines turn into reality. We have a lot of excitement about the potential upcoming adjuvant approvals of KEYNOTE-564 for renal cell carcinoma and KEYNOTE-716 for melanoma; in fact, here in the United States, we expect that through 2025, over half of KEYTRUDA's growth will come from indications in the early-stage setting, and that by that point they will make up roughly 30% of total contributed sales. Lynparza's revenue climbed 25%, and it remains the leading PARP inhibitor. That gain was driven by our breast cancer indication as well as continued uptake of the newest indications, including ovarian and prostate, and we expect a possible launch next year into a broader prostate population, supported by the PROpel trial. Lenvima revenue rose 30%. Within the United States, the increase came from renal cell carcinoma and endometrial cancer. We've observed quite promising early signals from the KEYNOTE-581 launch in first-line renal cell carcinoma. Beyond America's borders, the expansion we're seeing comes from rising demand after the NRDL listing in China this past March. We're also thrilled about the fresh approval of WELIREG for certain VHL-associated tumor patients. Scientific leaders, providers, and patients have given us tremendously favorable feedback regarding what WELIREG can do — it's off to a promising start — and going forward we hope to broaden WELIREG's reach into wider RCC indications. GARDASIL drove continued strong performance in our vaccines business, climbing 63% to $2 billion and gaining 35% so far this year. Stateside, most of that year-over-year increase reflected the timing of CDC purchases, which helped offset a back-to-school period that came in weaker than usual. Underlying demand for GARDASIL remains solid, and we're getting a bit of a lift as patients catch up on doses they missed during the pandemic. Outside the U.S., the growth was mainly driven by healthy underlying demand in China, along with increased supply and our ability to shift doses to where they're needed. Turning to hospital acute care, BRIDION sales were up 15%, fueled by our gains in market share within growing neuromuscular blockade reversal protocols. Now let's move to our outlook. Strong underlying demand for our products, together with our ongoing excellent commercial execution, gives us confidence about the outlook for our business. Merck has demonstrated greater urgency and agility throughout our organization, producing improvements that will make meaningful future growth possible. On GARDASIL, we still anticipate that robust ex U.S. demand and greater supply will fuel fourth quarter performance. We expect GARDASIL to show more normal seasonality, with the third quarter representing the highest in sales. Teams across the company have focused on establishing suitable procedures, allowing vaccine doses to be distributed properly toward regions where need has risen — particularly given that new coronavirus strains continue to hit specific parts of the world. Those patterns should drive a notably robust fourth-quarter increase for GARDASIL compared with a year earlier, powered by markets outside the United States, including China. Because HPV immunization rates worldwide are still modest, our view remains that GARDASIL holds considerable potential for expansion over the long run. On the oncology side, the results we delivered during the pandemic give us confidence — the headwind from fewer new patients beginning treatment was more than covered by our new product launches. We continue to believe in the fundamental demand for our wide-ranging, innovative lineup, which includes KEYTRUDA, Lynparza and Lenvima, and we anticipate delivering ongoing growth in major tumor types as well as in earlier lines of disease. Now, a few thoughts from me regarding what lies ahead for molnupiravir. As Rob said, we're genuinely enthusiastic about the chance to bring the first oral therapy to at-risk adults suffering from mild-to-moderate COVID-19, which could play a part in the fight against the pandemic. Merck is dedicated to making molnupiravir available broadly around the world, and the company is putting in place a pricing structure with different tiers that reflects World Bank income classifications for countries. So far, we have announced a number of commitments when it comes to supply and purchasing, and discussions continue with customers worldwide regarding similar deals. We also feel encouraged by the unanimous vote that came recently from the Advisory Committee on Immunization Practices. Should the CDC make this a final recommendation, then patients might receive the broadest possible safeguard, together with a strong immune response aimed at serotypes associated with about two-thirds of invasive pneumococcal disease cases in adults. When we consider our pneumococcal portfolio in a wider sense, the potential opportunity for VAXNEUVANCE in pediatrics—a bigger market segment—is something we're enthusiastic about. In closing, momentum within our business persists, fueled by demand and solid commercial execution, and our position is strong as we approach the year's end. Third-quarter growth highlights how confident we are in the fundamental strength of our business and worldwide demand for our innovative medicines and vaccines, and we're eager to sustain that growth well into the future. Having said that, I'll hand the call to Caroline.

Caroline Litchfield

executive
#4

Thank you, Frank, and good morning to everyone. The team delivered truly outstanding financial results during the third quarter. The money we're putting into our robust portfolio and pipeline, along with business development, is enabling us to produce superb near-term results while simultaneously setting us up to keep bringing forward significant innovations and long-term value for patients and shareholders. Moving on to our Q3 results now. Revenue for the entire company came in at $13.2 billion, which represents growth of 20%, or 19% when you strip out favorable foreign exchange effects. Everything else I say will be presented on an ex exchange basis. As Frank pointed out, momentum kept building in our Human Health business, which expanded 17%. Robust growth also came from our Animal Health business, where sales rose 14%, fueled by powerful worldwide demand in both companion animal and livestock. Companion Animal sales climbed 18%, powered by global demand in parasiticide, which includes the BRAVECTO product line, plus Companion Animal vaccines. Livestock sales were up 12%, mirroring solid worldwide demand for ruminant and poultry products, among them our Animal Health Intelligence products. I'll now take you through the rest of our P&L, and everything I say will be on a non-GAAP basis. Gross margin reached 76.8%, up 0.3 percentage points, which reflects a beneficial product mix effect that was partly offset by increased manufacturing costs. Operating expenses rose 11%, reaching $4.7 billion. Investments in our key growth pillars drove this, especially spending on supportive return to care activities and on our early and late-stage pipeline, molnupiravir included. Other expense grew by roughly $200 million because of greater pension settlement costs. The effective tax rate came in at 13%, down 1.4 percentage points, owing to discreet items. All told, we earned $1.75 per share, which is 26% higher. Let's move to our 2021 non-GAAP guidance. Although the pandemic keeps affecting numerous regions globally, patients and health systems have mostly adjusted, and we're assuming that pattern holds. Our guidance presumes the Acceleron transaction closes in the fourth quarter, contingent on the tender offer succeeding and regulatory approvals coming through, and it leaves out any potential sales or earnings from molnupiravir. Because our business is fundamentally strong, we can narrow and lift our anticipated revenue range to $47.4 to $47.9 billion, which means growth of 14% to 15%, and that figure incorporates an approximately 1.5% favorable foreign exchange impact based on mid-October rates. We anticipate gross margin of roughly 76.5%; our expectation for operating expense growth remains a high single-digit rate. For other income and expense, we're looking at approximately $450 million in expense. Our projection for the full year tax rate falls between 14% and 14.5%. We've assumed 2.54 billion shares outstanding. Putting it all together, we're raising and narrowing our EPS range to $5.65 to $5.70, which reflects substantial growth of 25% to 26%. This range incorporates an approximately 2% favorable foreign exchange impact based on mid-October rates. As you think about your models, here are a few areas to keep in mind. Let's begin with molnupiravir revenue. Looking ahead, we anticipate a worldwide opportunity of roughly $5 billion to $7 billion through 2022, and that figure includes $0.5 billion to $1 billion that we expect to realize during this year. That projection assumes emergency use authorization in December. Just as a reminder, any profit will be split evenly with our partner, Ridgeback. Merck handles recording global revenues and costs, and the profit share will show up within cost of sales. Turning to GARDASIL, momentum has been excellent, powered by strong demand and helped by the step function increase in supply that we are delivering this year. Sales in the fourth quarter are going to come in below the third quarter because of normal seasonality and timing effects; even so, we expect growth in the quarter to stay very robust. Animal Health has posted exceptional growth across the first 3 quarters of the year, helped in part by the pandemic's effect on pet adoption and pet spending; once we reach the fourth quarter, we will anniversary that effect, and as a result we expect a more normalized year-over-year growth rate. Our operating margin in the third quarter got a boost from very strong revenue performance, which includes the normal seasonality of our vaccine business. As we move through the fourth quarter, we expect operating margins to normalize because of this seasonality and phasing of spend. More broadly, looking out to 2024, we remain confident in our revenue potential and continue to believe it is underappreciated. And we remain on track to achieve our 2024 operating margin target of greater than 42%. Our capital allocation priorities remain unchanged; we will continue to invest in the business to drive the many significant near- and long-term growth opportunities we see in our derisk portfolio and rich pipeline; we also continue to execute on our business development strategy, including our announced acquisition of Acceleron. We will pursue additional value-enhancing and strategic business development opportunities, and we retain significant balance sheet capacity to do so; we remain committed to the dividend with the goal of increasing it over time. To the extent we have excess cash, we will return it to shareholders through share repurchases. To conclude, Merck continues to make exceptional progress on its commitment to drive growth and value for patients and shareholders; we remain in a position of financial and operational strength, which will enable us to deliver on that promise now and well into the future. With that, I'd now like to turn the call over to Dean.

Dean Li

executive
#5

Thanks, Caroline. Morning, everyone — glad to be joining you and to walk through how things have gone since the call we held last quarter. I'll start with news on our oral antiviral candidate molnupiravir, then move to the proposed Acceleron acquisition, shine a light on some recent advances with islatravir, and wrap up with a rundown of key regulatory milestones and clinical updates from throughout the pipeline. Extra therapeutic choices are still essential in the fight against the COVID-19 pandemic. Our Phase III trial MOVe-OUT, which is assessing molnupiravir in at-risk, nonhospitalized patients suffering mild-to-moderate COVID-19, produced an interim analysis showing a reduction of roughly 50% in the risk of hospitalization or death relative to placebo. What stands out is that through day 29, there were no fatalities in the molnupiravir group, compared with 8 deaths among those on placebo. That makes it the first oral antiviral for a respiratory virus to deliver a benefit based on strong clinical outcomes, and also the first to show a meaningful 5-day window for treatment after symptoms appear. Because the results were so favorable, the study stopped enrolling patients ahead of schedule, following a recommendation from the Independent Data Monitoring Committee and consultation with the FDA. Armed with this data and facing the pressing nature of the pandemic, our teams put in relentless effort and, within 10 days of getting the data, filed a robust package with the FDA seeking EUA. We're eager to talk about the EUA submission when the Antimicrobial Drugs Advisory Committee meets on November 30; until then, we'll keep working with the FDA to help with its review. We've also filed applications with regulators in many other countries. I'd like to pause and express thanks to the investigators, the patients and their families who took part in MOVe-OUT. My appreciation also goes out to our partners at Emory University and Ridgeback, plus the teams within Merck, for the tremendous effort they put into running this program through such a difficult period. Broad vaccination continues to be the most viable long-term approach for tackling the COVID-19 pandemic. Administering a pill at home soon after symptoms appear might offer one more meaningful choice for patients, health care systems and public health — something that could deliver a sizable, beneficial effect on the pandemic. Drawing on helpful viral sequence information, molnupiravir demonstrated steady effectiveness against the gamma, delta and the new COVID-19 variant. A reminder: we are still actively enrolling people in the MOVe-AHEAD trial, which is assessing the safety and efficacy of molnupiravir and stopping COVID-19 transmission among household members as a post-exposure prophylactic, with results expected in the spring of 2022. Now let's discuss the proposed Acceleron acquisition. Acceleron brings a strong scientific track record, and that work has already produced a meaningful anemia therapy for adults dealing with specific uncommon blood conditions. Sotatercept, their most advanced clinical prospect, could become a cornerstone add-on treatment for pulmonary arterial hypertension, and it would fit nicely alongside the cardiovascular pipeline we're expanding. After the deal is finalized, the intention is to advance the extensive Phase III clinical effort. Switching now to the portfolio and pipeline, starting with HIV: we continue to generate clinical results that reinforce islatravir's foundational potential in HIV. This week at the European AIDS Conference in London, we shared results from the Phase II study of doravirine and islatravir in adults with HIV infection who had not been treated before, and those data showed viral suppression maintained out to 144 weeks. We also recently announced positive top line findings from 2 pivotal trials of a once-daily oral doravirine plus islatravir regimen in a SWITCH setting among adults with HIV infection who are virologically suppressed on another HIV therapy regimen. Looking at week 48 data, the primary efficacy goal was met in both studies—specifically regarding the proportion of patients whose HIV RNA stayed at or exceeded 50 copies/mL—and the results demonstrated effectiveness on par with individuals receiving the comparator antiretroviral regimen. We plan to present this information at a forthcoming medical congress and file it as part of our worldwide regulatory submission. Additionally, we announced this week that a Phase II trial has begun for an oral regimen taken once weekly, combining islatravir with lenacapavir, among HIV-positive individuals whose virus is suppressed while on antiretroviral treatment. Our collaboration with Gilead has moved forward substantially, and we are eager to provide updates on upcoming milestones, including our injectable long-acting co-formulation. Turning to VAXNEUVANCE now. For people 18 and older, we received a favorable opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. Then, more recently in the U.S., the CDC's ACIP cast a unanimous vote to give a provisional recommendation for VAXNEUVANCE followed by PNEUMOVAX, as a choice for pneumococcal vaccination among adults 65 and up, as well as adults between 19 and 64 who have specific underlying medical conditions — our clinical trials studied both of those patient groups. A vaccine's performance has multiple dimensions: it involves both generating a robust immune response and delivering coverage against serotypes that matter for disease. A two-dose schedule gives us the advantages of both approaches: it triggers a strong immune response against all 15 serotypes contained in VAXNEUVANCE, serotype-3 included, and it delivers the widest serotype coverage available from any pneumococcal vaccine on the market today — four of those serotypes are found only in PNEUMOVAX. On top of that, among the recently licensed TCVs, VAXNEUVANCE comes with the largest clinical development program. That program covers finished or active studies in patients who have particular chronic conditions or compromised immune systems, which make pneumococcal disease both more likely and more severe. We also shared positive top line results for VAXNEUVANCE from the pivotal PNEU-PED trial, which looked at immunogenicity, safety and tolerability in pediatric patients, and we've filed an application with the FDA. The data show that adding serotypes 22F and 33F, plus robust immunogenicity targeting serotype 3, could be significant in stopping pneumococcal illness among infants and children. Among kids under five, those three serotypes make up more than 25% of all invasive disease cases. We'll present the full results at an upcoming scientific congress; and finally, turning to oncology. The flood of data from our clinical development programs across multiple tumor types continues. Our progress in generating new therapeutic options for women's cancer carries on, after KEYTRUDA plus chemotherapy, with or without bevacizumab, won approval for recurrent or metastatic cervical cancer, backed by KEYNOTE-826 results. This research showed a 36% reduction in mortality risk, which is significant. When it comes to first-line treatment, this is the first anti-PD-1 combo option available, and together with our market-leading HPV vaccines, GARDASIL and GARDASIL 9, we're in a distinctive spot to address particular gaps in cervical cancer care, with a focus on both stopping it and treating it. Back in September at ESMO, we presented the final data from KEYNOTE-355, the study testing KEYTRUDA plus chemo in advanced triple-negative breast cancer, which showed a 27% decrease in the risk of dying. KEYTRUDA is the only immuno-oncology treatment that has received approval for metastatic triple-negative breast cancer. Together with further data shared regarding endometrial and ovarian cancers, this strengthens the extraordinary advancement occurring within our extensive women's cancer portfolio.

Dean Li

executive
#6

We're also gaining ground in additional cancer types, such as prostate cancer. Together with our collaborators at AstraZeneca, we shared encouraging findings from the Phase III PROpel trial involving first-line therapy for metastatic castration-resistant prostate cancer; that trial showed Lynparza, when paired with abiraterone, markedly held back disease progression no matter what a patient's biomarker status was. In this context, Lynparza becomes the initial PARP inhibitor to show clinical advantage in radiographic progression-free survival alongside a novel hormonal agent. This trial and the chance to assist the growing population of men given a diagnosis of metastatic castration-resistant prostate cancer leave us optimistic. Data are going to be shared at a forthcoming medical conference and filed with regulatory bodies worldwide. Moving on to renal cell carcinoma, an important field for our expansion; in August, the FDA gave us approval for WELIREG, a first-in-class HIF-2 alpha inhibitor treatment intended for adult patients with Von Hippel-Lindau disease who need therapy for associated renal cell carcinoma, central nervous system, hemangioblastomas or pancreatic neuroendocrine tumors, not requiring immediate surgery; that clearance gives us a <<inaudible>> as we assess WELIREG's potential along with broader RCC indications and beyond. Also within RCC, working alongside Eisai, after FDA priority review, we gained approval for combining KEYTRUDA and Lenvima in the first-line setting, drawing on findings from the KEYNOTE-581 trial. This delivers a significant new first-line therapeutic choice for those with advanced RCC; we're likewise swiftly broadening programs into earlier lines of therapy. Over the quarter, the FDA gave priority review to our submission for KEYTRUDA as an adjuvant treatment for patients with RCC at intermediate high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions from the KEYNOTE-564 study. In addition, we obtained priority review for KEYTRUDA to treat patients with surgically resected high-risk Stage 2 melanoma, based on findings from the KEYNOTE-716 study that revealed better recurrence-free survival versus placebo. These two studies show the value of widening KEYTRUDA's use into earlier stages of disease, letting us bring treatment benefits to more patients sooner; we anticipate a decision on both studies by the end of the year. In closing, I take pride in the advances throughout our extensive pipeline and anticipate sharing additional updates on our scientific progress down the road. I'll now hand the call back to Peter.

Peter Dannenbaum

executive
#7

Thanks, Dean. Grace, would you mind kicking off the Q&A section? Also, I'd ask those asking questions to stick to 1 question apiece today, so we can fit in as many different questions as we can.

Umer Raffat

analyst
#8

Since you'll cover other topics later in the call, I'll focus my question on KEYTRUDA in adjuvant lung. Has an interim analysis occurred? Does the staff's plan permit a hierarchy in which PD-L1 positive patients come first? And do you anticipate that the benefit will appear both in patients who received adjuvant chemo and in those who did not?

Frank Clyburn

executive
#9

Yes. Thanks so much. I'm grateful for that question. To start, let me highlight something briefly. The emerging data on what PD-1s and PD-L1s can do in early treatment and the adjuvant setting has us excited. We're pleased that in renal, melanoma, and breast cancer, effects appear substantial. Those are cancers for which early screening methods are often used; when it comes to lung specifically, we hold a leading position in lung cancer. Within lung cancer, treating later-stage disease is the stage that predominates. As you hinted regarding other companies, the data suggest that in lung cancer, this PD-1, PD-L1 class might work in early and adjuvant settings. Specifically, with respect to — we have several early and adjuvant stage lung cancers, and the slide listed them. KEYNOTE-091 is also called the PEARLS trial. KEYNOTE-091 PEARLS is a study run collaboratively with the European Organization for Research and Treatment of Cancer. Merck is a collaborator on this trial. This study is event-driven, and we're in active communication with EORTC, and together, we await data from the IA2 before the end of the year, and I'd venture to guess that any public announcement from Merck would come at the beginning of the new year.

Peter Dannenbaum

executive
#10

Great. Thank you, Umer. Next question, please.

Daina Graybosch

analyst
#11

I'd like to ask a question about molnupiravir, possibly with 2 parts, regarding how you're proceeding. First, questions have come up in public regarding genotoxicity, so I'm curious whether you could speak to the evidence you hold that leads you to feel unconcerned about it. Then the second issue would be resistance, perhaps, and I'm wondering how you view the future along with combinations, and whether that might be necessary to stop any resistance, perhaps stemming from poor compliance with molnupiravir.

Dean Li

executive
#12

Yes. Thanks for asking that. This is Dean. I'd simply stress that we hold great confidence regarding molnupiravir's safety profile, grounded in our preclinical and clinical data. With respect to the clinical data, I believe most people acknowledge that during the interim analysis, we saw a profound drop in hospitalization or death relative to placebo, and it was halted early in — under the DSMB's guidance and after consultation with the FDA. And within that interim analysis, the rate of any adverse effect was similar between molnupiravir and placebo. And in fact, if you examine it, a few subjects in the molnupiravir arm stopped therapy because of an adverse event, versus the placebo arm. Regarding our confidence in the safety profile, which rests on our extensive preclinical evaluation, I think it's key to acknowledge that molnupiravir is a nucleoside analog whose mechanism involves producing errors within the genetic material of RNA viruses. Such nucleoside analogs are frequently employed in numerous other antiviral treatments, such as HIV and hepatitis; and we've conducted a comprehensive nonclinical program to characterize molnupiravir's safety profile. Other people have written about it. It has actually also been written about in scientific journals, and we will present all of this data, I believe, at the AdCom that the FDA will be holding; but likely the most important pieces of information are the — in 2 distinct in vivo rodent mutagenicity assays, commonly called the Big Blue and the Big A, which are well characterized and regarded as providing a robust measure of a drug's or chemical's ability to induce mutations in vivo. In these studies, we're giving molnupiravir for longer periods and at higher doses than those used in the human clinical trial. And the totality of the data from these studies indicate that molnupiravir is not mutagenic or genotoxic in these in vivo mammalian systems. Now we have shared these results throughout with regulatory agencies worldwide, and we'll keep providing additional data as this process continues.

Peter Dannenbaum

executive
#13

Great. Thanks, Dean.

Andrew Baum

analyst
#14

I've got some questions for Frank regarding molnupiravir. When it comes to supply, it seems to me that with the manufacturing enhancements that have been published and a dose of 4 grams per patient, 20 million appears to be quite a cautious projection, especially when you factor in third parties and what might be possible based on the dosing and the API. Could you please share your thoughts on what the actual supply for 2022 might be? Then secondly, maybe you could weigh in on how interested Merck is in pursuing direct-to-consumer advertising or other promotional efforts for molnupiravir. My understanding is that under an EUA, promotion and advertising are permitted — if you could verify whether that's true or not, that would be excellent.

Frank Clyburn

executive
#15

Yes, Andrew, it's Frank here. A few points I'd like to emphasize: first, we have line of sight to manufacture 10 million courses in 2021, Andrew, this year; and as we've said, we have that line of sight and at a minimum we'll double it in 2022. So to address your question, we'll do whatever we can to boost supply of this product. Beyond that, there are voluntary license partners, as you've seen, plus we're collaborating with a number of partners to deliver global supply. So rest assured, Andrew, on the supply side we're going to attempt everything possible. Regarding direct-to-consumer, I believe it's somewhat early for us on that front; no decision has been made about it. Our real focus is on doing all we can to secure agreements with governments, make the product available around the world, and we'll share more information as we move forward on molnupiravir, but for the company this is our #1 priority, and it's something we're genuinely eager to pursue in trying to help address the ongoing pandemic.

Rob Davis

executive
#16

Rob here, Andrew. I want to be certain about this, since hearing your question, I believe Frank already addressed it, but let me stress it in case other people on the call aren't picking up on it. That $20 million, or rather the statement about more than doubling our capability in the coming year, refers to Merck's own output. None of those figures account for the 8 voluntary license partners located in India, and they also don't include anybody the Medicines Patent Pool brings on board. So clearly, worldwide supply of molnupiravir is going to be considerably larger next year. What we're addressing is simply the quantities we at Merck will manufacture.

Frank Clyburn

executive
#17

I want to mention one additional point, since I realize this ties into the earlier question as well, and it has to do with our scientific thinking on molnupiravir during the pandemic phase. There will also be an endemic phase, and possibly further phases beyond that; however, regarding the pandemic phase, I want to stress that we have the MOVe-OUT trial, and after that we will need to look at what MOVe-AHEAD might offer to determine if we end up with both a therapy and prophylaxis; once we reach the endemic phase, as the pandemic gradually subsides, SARS-CoV-2 very likely will turn into an endemic infection. All of us must acknowledge, and this connects to the prior question, that throughout this phase, a substantial global reservoir of people will carry high copy numbers of the virus, and in many of those people this could produce a continual brewing of variance; therefore the matter of resistance takes on great significance. It matters to point out that molnupiravir carries an extraordinarily high barrier to resistance; it demonstrates broad efficacy against every SARS-CoV-2 variant identified so far. Moreover, in our preclinical work and in preclinical work done by others, it shows not only wide-ranging efficacy across SARS-CoV-2 variants, but also across a wide array of RNA viruses, and likely the widest range among all other mechanisms currently known to be in development. I should stress that this high barrier to resistance is of critical importance, in both the pandemic phase and the endemic phase, as has been noted, and I must emphasize that for this reason, we gave molnupiravir priority over our other programs, which includes an internal protease inhibitor, because of the paramount importance we assign to securing the highest barrier to resistance given the situation the world faces at present.

Peter Dannenbaum

executive
#18

Great. Thank you, Andrew. Next question, please, Grace.

Carter Gould

analyst
#19

Not a shock, my questions will center on that topic. Perhaps for Frank and Caroline, I want to pin down precisely what assumptions underlie that guidance regarding what will be shipped next year across your supply, intersecting that with — as you put it — the provision of doses to lower- and middle-income nations via the MPP. I realize tiered pricing is part of this, yet it appears you'll still fall well short of moving your entire capacity; so any insight there would be appreciated.

Frank Clyburn

executive
#20

Sure, Carter, Frank here. I'll take the first pass and let Caroline chime in if she has anything to add. In our modeling, and I recognize this remains quite a fluid circumstance, we build in an Early Use Authorization this December; contracts already executed are counted, plus those currently in negotiation. That gives us confidence in the $5 billion to $7 billion range through '22; and to underscore once more, those figures rest on signed agreements, deals in line of sight, and others likely to be executed. A few more points, as we've stated and Rob echoed, we'll manufacture 10 million courses of therapy before '21 closes and have pledged to at minimum double that during '22. Our initial priority — and this matters — is the COVID-19 treatment. You brought up broad global access, which indeed involves tiered pricing internationally, and that's a key element: pricing will be tiered according to affordability measures. Should our post-exposure prophylactic trial succeed, as Dean pointed out, with data expected in spring, these estimates could see upside. Also, across 2022, we aren't assuming — to address your question — that every bit of supply gets utilized. Because of that, we can serve extra demand. We likewise anticipate other oral antivirals entering the market, and only time will tell how that plays out. We're eager to share more specifics and clarity as we gain further understanding in the coming months.

Peter Dannenbaum

executive
#21

Thank you, Carter. Next question please, Grace.

Steve Scala

analyst
#22

Merck sees itself as sitting in a strong spot when it comes to pneumococcal vaccines, yet ACIP didn't seem to share that view — they didn't treat the cost benefit of the 20-valent as better, even if you assume it doesn't work against serotype 3. So in Merck's eyes, where did ACIP get it wrong? And what does Merck do to shift that story?

Dean Li

executive
#23

To start, our confidence in V114 VAXNEUVANCE is very high. There are 2 areas where we're pushing it forward. That's in adult and pediatrics. As you're aware, the pediatric market — and I'll have Frank address this — is a quite robust market, and our program is moving ahead. We've filed with the FDA, and we expect to hear back from them shortly; so pediatrics is a big focus for us; when it comes to adults, the key matter for us regarding <<inaudible>> is that, as I mentioned in the prepared comments, I believe it's very important to provide the best coverage in terms of serotypes, but not only through immunogenicity — through actually studying clinical events, particularly in those patients who are compromised or at risk or have some other condition that might raise their susceptibility to invasive pneumococcal disease. And we believe that clinical data and the way we studied it in these patient populations directly. We haven't extrapolated from immunogenicity. We actually studied it; that is something critically important when one looks at a vaccine's true efficacy. Frank, would you like to respond?

Frank Clyburn

executive
#24

Yeah. The one point I'd like to make is that we felt quite happy about the unanimous backing for the VAXNEUVANCE and PNEUMOVAX sequence. In our view, that sequence gives patients the widest protection available, delivering robust immune responses against serotypes behind 2/3 of adult pneumococcal disease, and the ACIP also pointed out that the regimen was cost effective and cost saving among patients 65-plus. Then, as Dean said, we're also very enthusiastic about what VAXNEUVANCE could do in the pediatric segment, which we see as the bigger market opportunity. So on the whole, from where we sit, we feel quite positive about the ACIP's recommendation.

Peter Dannenbaum

executive
#25

Thank you, Steve. Next question, please, Grace.

Geoffrey Meacham

analyst
#26

You brought that up somewhat. During the initial call, you mentioned molnupiravir a bit; however, in what way do you anticipate planning <<inaudible>> relative to the booster approach for the vaccine? Would you anticipate additional official guidance from the CDC or other health agencies regarding how molnupiravir might suit the algorithm?

Frank Clyburn

executive
#27

Perhaps I'll take this one. Geoff, my apologies, you came through somewhat garbled. I'll restate what I believe your question was, then you can correct me if I misunderstood. I believe you asked, this is the first oral antiviral. Yet clearly, we still have vaccines available that matter as truly the initial line, and do we think any conversation exists about how this will suit the regimen. I don't believe we can truly say anything about how Advisory Committees, the FDA or others, the CDC might view that. However, what I will say from our standpoint, above all, people ought to be vaccinated that it keeps believing what we consider the correct response. We view our therapy as an important supplement to the armamentarium. And clearly, there are situations where individuals cannot receive the vaccine or sadly, if individuals get vaccinated and experience breakthrough virus; so there's certainly a need for this, but it is in collaboration as a complement to the vaccine not in place of it. That's our standpoint. We'll allow the government to speak to their own.

Peter Dannenbaum

executive
#28

Thank you, Geoff. Next question, please, Grace.

Chris Schott

analyst
#29

I'm just attempting to wrap my head around GARDASIL and what came through in the quarter; could you clarify or put some numbers behind how much of that $2 billion in sales for this quarter came from stocking as opposed to underlying demand? And on a broader level, are we still in a situation where, on a global basis, demand is outpacing supply, I suppose, when we consider the capacity expansion that happened recently? And I suppose I'm trying to wrap my head around whether this franchise will see another jump in sales as we look toward 2023 and past that with the new facility coming online? Or have the capacity efforts you've already made kind of taken care of most of the demand that exists out there.

Caroline Litchfield

executive
#30

So Chris, it's Caroline here. I'll begin, then pass it to Frank. So during the quarter, as you're aware, we had an exceptional quarter, and that came from strong global demand along with the step-up in supply we have. We also gained from CDC timing, which amounted to roughly $125 million of buy-in during the third quarter of this year; and that's in contrast to a buy-out in the third quarter of 2020. So on a year-over-year basis, we believe we've gained by around $180 million to the results. Now regarding how we view this moving forward, we're quite excited about the opportunity. We see chances for greater supply through '22 and past that as we see additional capacity come online. But let me pass it to Frank to discuss the demand that we have.

Frank Clyburn

executive
#31

Sure, Chris — I appreciate the question. There are a few additional points I'd like to emphasize when you're considering GARDASIL, and we've actually been talking about this for some time: namely, the short-term performance you brought up, alongside what we expect over the longer haul. To begin, let me point out that just 9% of what we regard as the eligible population worldwide has received the vaccine; so, Chris, that's my starting point, and I'd say a considerable opportunity remains for us. And when you look at places like China, or consider the green light in Japan, or think about the gender-neutral possibilities across Europe, plus the additional age groups — adults and mid-adults — in the U.S., we believe there's substantial room for GARDASIL to keep growing. You observed an increase in our supply, and that will persist; the pace will be somewhat more measured in the coming year; but you can be sure that once we start up the 2 new bulk manufacturing facilities in '23, that's precisely why we see the long-term growth outlook for GARDASIL as extremely meaningful, and it's going to serve as a major growth engine for the company in the years ahead.

Peter Dannenbaum

executive
#32

Thank you, Chris. Next question, please, Grace.

Tim Anderson

analyst
#33

I want to ask about further M&A. This is probably for Rob. During that Acceleron investor call you had, I raised the possibility of Merck pursuing more M&A even if it resulted in a ratings debt downgrade. Your response was quite candid — you said yes. Yet the company hasn't been inclined to sort of put numbers on how much extra debt might potentially be the amount that sets off a downgrade. From what I understand, an additional $10 billion cash deal would be sufficient to set off a 1-notch downgrade. And in a scenario involving roughly a $30 billion cash deal, that might mean a 2-notch downgrade. So what I'm asking now is whether Merck would truly pursue a deal large enough to bring about a 2-notch ratings downgrade.

Rob Davis

executive
#34

Thanks for that question. Let me begin at a higher level. Are we still going after additional business development? Yes, we are; the driver will be, just as it always has been, whatever strikes us as a compelling scientific opportunity, where science is addressing an unmet need, where there's strategic alignment with us, and where we're able to bring value. So nothing there has changed; and when we consider capacity, all I'd say is that we think we possess the firepower to do — honestly — any deal out there that we'd have a strategic interest in pursuing. For us, the balance sheet won't act as a rate limiter. Our balance sheet capacity is very strong. I don't believe we want to get pulled into trying to nail down specifics. Honestly, a number of your figures were pretty far off, in fact, but I'd rather not begin digging into that sort of detail, since it hinges on rating agencies. It hinges on the cash flows coming from the target. So with that said, the key takeaway is that balance sheet capacity is not something that will constrain us.

Seamus Fernandez

analyst
#35

So, I've got one quick question about the pipeline at the earlier stages. I was somewhat taken aback that you're presenting your first oral PCSK9 inhibitor in a late-breaker at AHA in 2 weeks, yet it doesn't appear in your pipeline summary. Can you help us figure out why that is? And as a follow-up, when could we expect to learn more regarding the earlier-stage pipeline? Would that happen at an R&D Day in 2022? What's the appropriate moment to begin, I suppose, revealing a bit more of the earlier-stage pipeline that Merck has been assembling over the last 3 to 4 years through acquisition and then internally?

Rob Davis

executive
#36

Yes. This is Rob. Perhaps I'll have Dean speak specifically about the oral PCSK9, and then I can address your question about additional transparency.

Dean Li

executive
#37

Absolutely — regarding the oral PCSK9 specifically, that program is headed to the American Heart Association, and it's moving into a Phase II. That's the reason our pipeline frequently lists it at Phase II, yet we're aiming to show greater transparency by presenting something that's on the verge of stepping into that phase. The presentation at the American Heart Association, in my view, will draw a strong crowd. In my view, the effort to develop an oral PCSK9 has long been something of a holy grail within the cardiovascular field, and nobody has managed it, while we think we have. It concerns that product, but it also speaks to Merck's ability to accomplish what others cannot; and when someone examines how we built that molecule, they'll instantly wonder, wow, what kind of capacity is that? What technology enables them to pull that off for PCSK9? Which other targets might they also be pursuing? Bob?

Rob Davis

executive
#38

Yes, thank you. And like Dean pointed out, our perspective is that once programs advance from Phase I to Phase II, that's the point where we'll begin talking about them, so this is simply part of that ongoing process. And I want to emphasize that in order to get into it, there is a great deal — we have additional assets in cardiovascular that have either already advanced or are advancing into Phase II. That's the reason we genuinely view our cardiovascular pipeline as an expanding source of enthusiasm and strength, and the reason we were so thrilled by how complementary Acceleron is to that pipeline. On the transparency question, here's what we're planning: the next space we want to focus everyone's attention on is cardiovascular, since I genuinely feel excited about the assets we hold there. There's a substantial amount in motion that, in my view, hasn't gotten the credit it deserves. Obviously, our preference is to hold off until the Acceleron transaction is finalized, which would let us fold their assets into that discussion — and we'll do that the moment we can pin down the timing, whether that lands in the latter part of this year or the beginning of the next. Looking further ahead, I felt really good about the results we delivered when we increased — when we shone a brighter light on our HIV pipeline. The excitement surrounding islatravir is a core, foundational driver for us. In oncology, we continue to have a number of ways to make an impact, through KEYTRUDA as well as a growing set of novel mechanisms. That's something we've pointed out. And after we move beyond cardiovascular, my guess is we'll begin discussing our CNS portfolio, since we also have substantial assets in neurology, which I find quite promising. So our approach is to go therapeutic area by therapeutic area as programs begin advancing into the Phase II stage, and we'll move them forward as fast as possible, with cardiovascular leading the way once Acceleron is complete.

Peter Dannenbaum

executive
#39

Thanks, Seamus. It's just gone 9 o'clock. In my view, there's room for one additional question. Grace, let's take the next one, please.

Louise Chen

analyst
#40

So a number of companies are attempting to launch checkpoint inhibitors at cheaper prices. And in your view, will those lower-price approaches gain any real traction? What makes you say that?

Frank Clyburn

executive
#41

Frank here — I'll come at that from a few angles. I'm aware that this has been a topic of discussion. And what I want to do first is make sure we keep stressing that what we observe in oncology is genuinely driven by data. Along with how much strong clinical data matters, and I believe you've watched that put us in a good spot, plus the mountain of evidence we've built around a product such as KEYTRUDA, which has 33 indications at present, and simply the familiarity and the expansion we're seeing across so many cancer types that I was pointing to, we believe our position is very strong. We also believe that as KEYTRUDA picks up more approvals, the regulatory part for new entrants grows. And with physicians steadily building experience, our thinking is that a wider structural shift would also be needed in the U.S. for broad adoption to happen. So from our standpoint, we'll keep watching the competitive landscape, just as we always have, but when it comes to KEYTRUDA and our growth prospects ahead, our confidence is very high.

Peter Dannenbaum

executive
#42

Great. Thanks, Louise. Rob, any final points?

Rob Davis

executive
#43

Absolutely. Perhaps just a few things. To start, I'd like to express gratitude to and acknowledge the Merck team members around the world for their efforts and commitment during the pandemic. The manner in which we've managed to deliver, I believe, truly demonstrates the finest of who we are, and I couldn't feel more pride in every aspect of our operations—clinical, commercial, manufacturing—it's genuinely extraordinary. So I do want to begin by acknowledging them, since I believe that matters; and ideally, what you gathered from this call is that this is a thrilling moment for Merck. We truly possess escalating momentum, and I can tell you, escalating conviction that we're capable of expanding not only in the short term, but with a widening collection of assets that position us to sustainably remain a meaningful contributor to human health and to keep providing considerable value to our shareholders. We're a more concentrated organization. We're an organization growing more quickly. We're operating with urgency to fulfill our mission and deliver for patients and shareholders. So ideally, that resonated; and I'm also quite delighted by how much advancement we've achieved within a brief span. You've heard today about favorable progress throughout our businesses, but progress—favorable progress and producing an exceptionally robust quarter, advancing rapidly with what we're doing regarding molnupiravir, excellent outcomes arriving with islatravir and our wider oncology portfolio. So we're operating at full capacity, and I'm confident and proud of our position, and I appreciate your time.

Operator

operator
#44

Thanks. That wraps up the conference call for today. Appreciate everyone for being on the line. At this point, you're all free to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.